RxDoctor Payments Data

Adam Bard, MD

Internal Medicine · Fairfield, CTNPI 1477531218

Payments from drug & device makers

$2,727in general payments, 2019–2025

Across 139 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$740
  • AstraZeneca$642
  • Novo Nordisk$171
  • Pfizer$171
  • Amgen$152
  • Vanda Pharmaceuticals Inc.$147
  • plus $703 from 12 others

What the payments were for

  • Food & beverage$2,727100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,727 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$403,822
Medicare patients
332
Services billed
5,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$114,474
JanuviaSitagliptin Phosphate57$77,765
MounjaroTirzepatide65$72,681
FarxigaDapagliflozin Propanediol59$68,579
JardianceEmpagliflozin42$54,141
EliquisApixaban50$49,890
JanumetSitagliptin Phos/Metformin Hcl43$36,504
XareltoRivaroxaban19$20,957
MyrbetriqMirabegron18$16,737
Atorvastatin Calcium764$7,434
VascepaIcosapent Ethyl14$3,746
Rosuvastatin Calcium275$3,450
Carvedilol ErCarvedilol Phosphate12$3,406
SynthroidLevothyroxine Sodium43$3,254
Amlodipine Besylate500$2,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$171$114,47495 claims
MerckJanuvia, Janumet$109$114,269100 claims
Lilly USA, LLCMounjaro$48$72,68165 claims
AstraZenecaFarxiga$642$68,57959 claims
PfizerEliquis$171$49,89050 claims
Johnson & JohnsonXarelto$13$20,95719 claims
AbbVieSynthroid$740$3,25443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →